Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARQT Arcutis Biotherapeutics	$13.65 -4.7%	$14.76	$6.99 ▼ $17.75	$1.63B	1.87	2.38 million shs	4.60 million shs
BBIO BridgeBio Pharma	$35.82 -3.0%	$34.23	$21.62 ▼ $39.54	$6.80B	1.15	2.37 million shs	3.73 million shs
BPMC Blueprint Medicines	$99.84 +0.7%	$88.14	$73.04 ▼ $121.90	$6.40B	0.83	774,602 shs	906,170 shs
TLX Telix Pharmaceuticals Limited American Depositary Shares	$17.75 -2.9%	$17.14	$13.61 ▼ $30.36	$6.00B	N/A	27,381 shs	47,934 shs

10 Stocks Set to Soar in Spring 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARQT Arcutis Biotherapeutics	-4.71%	-8.48%	-4.58%	+9.86%	+73.16%
BBIO BridgeBio Pharma	-3.02%	-6.61%	+16.80%	+9.55%	+28.91%
BPMC Blueprint Medicines	+0.69%	+11.55%	+24.49%	-8.92%	-8.02%
TLX Telix Pharmaceuticals Limited American Depositary Shares	-2.90%	+2.01%	+24.56%	-2.95%	+1,774,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARQT Arcutis Biotherapeutics	2.9603 of 5 stars	4.4	2.0	0.0	0.0	3.2	0.8	0.6
BBIO BridgeBio Pharma	4.5987 of 5 stars	4.5	1.0	0.0	3.9	3.3	4.2	0.6
BPMC Blueprint Medicines	2.5297 of 5 stars	4.4	1.0	0.0	0.0	2.7	0.8	0.6
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARQT Arcutis Biotherapeutics	2.83	Moderate Buy	$18.80	37.78% Upside
BBIO BridgeBio Pharma	2.92	Moderate Buy	$57.09	59.36% Upside
BPMC Blueprint Medicines	2.83	Moderate Buy	$126.56	26.77% Upside
TLX Telix Pharmaceuticals Limited American Depositary Shares	3.00	Buy	$22.00	23.94% Upside

Current Analyst Ratings Breakdown

Latest ARQT, BBIO, BPMC, and TLX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/2/2025	BPMC Blueprint Medicines	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$135.00 ➝ $135.00
5/1/2025	BPMC Blueprint Medicines	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$128.00
4/30/2025	BBIO BridgeBio Pharma	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$46.00 ➝ $63.00
4/30/2025	BBIO BridgeBio Pharma	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$52.00 ➝ $55.00
4/30/2025	BBIO BridgeBio Pharma	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$65.00 ➝ $72.00
4/28/2025	BPMC Blueprint Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$133.00 ➝ $130.00
4/16/2025	BPMC Blueprint Medicines	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$128.00 ➝ $128.00
4/15/2025	BBIO BridgeBio Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$49.00 ➝ $53.00
4/9/2025	ARQT Arcutis Biotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
4/8/2025	BPMC Blueprint Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$133.00 ➝ $133.00
4/3/2025	ARQT Arcutis Biotherapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy

(Data available from 5/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARQT Arcutis Biotherapeutics	$196.54M	8.28	N/A	N/A	$0.94 per share	14.52
BBIO BridgeBio Pharma	$127.42M	53.39	N/A	N/A	($7.71) per share	-4.65
BPMC Blueprint Medicines	$562.12M	11.47	N/A	N/A	$4.67 per share	21.38
TLX Telix Pharmaceuticals Limited American Depositary Shares	$783.21M	7.66	N/A	N/A	N/A	∞

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARQT Arcutis Biotherapeutics	-$262.14M	-$1.16	N/A	N/A	N/A	-140.97%	-119.11%	-45.95%	N/A
BBIO BridgeBio Pharma	-$535.76M	-$3.53	N/A	N/A	N/A	-241.44%	N/A	-75.69%	N/A
BPMC Blueprint Medicines	-$67.09M	-$2.47	N/A	153.60	N/A	-13.19%	-77.49%	-20.84%	N/A
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A	N/A	0.00	36.98	N/A	N/A	N/A	N/A	N/A

Latest ARQT, BBIO, BPMC, and TLX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/6/2025	Q1 2025	ARQT Arcutis Biotherapeutics	-$0.21	-$0.20	+$0.01	-$0.20	$64.80 million	$65.85 million
5/1/2025	Q1 2025	BPMC Blueprint Medicines	-$0.42	-$0.74	-$0.32	$0.01	$158.31 million	$149.41 million
4/29/2025	Q1 2025	BBIO BridgeBio Pharma	-$1.00	-$0.88	+$0.12	-$0.88	$57.14 million	$36.74 million
2/25/2025	Q4 2024	ARQT Arcutis Biotherapeutics	-$0.28	-$0.09	+$0.19	-$0.09	$60.52 million	$71.36 million
2/20/2025	Q4 2024	BBIO BridgeBio Pharma	-$1.09	-$1.31	-$0.22	-$1.40	$4.04 million	$5.88 million
2/20/2025	Q4 2024	BPMC Blueprint Medicines	-$0.68	-$0.79	-$0.11	-$0.79	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARQT Arcutis Biotherapeutics	N/A	N/A	N/A	N/A	N/A
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
BPMC Blueprint Medicines	N/A	N/A	N/A	N/A	N/A
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARQT Arcutis Biotherapeutics	0.67	2.46	2.38
BBIO BridgeBio Pharma	N/A	4.67	4.67
BPMC Blueprint Medicines	1.15	2.85	2.80
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARQT Arcutis Biotherapeutics	N/A
BBIO BridgeBio Pharma	99.85%
BPMC Blueprint Medicines	N/A
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A

Insider Ownership

Company	Insider Ownership
ARQT Arcutis Biotherapeutics	9.50%
BBIO BridgeBio Pharma	24.66%
BPMC Blueprint Medicines	4.21%
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARQT Arcutis Biotherapeutics	150	119.20 million	105.93 million	Optionable
BBIO BridgeBio Pharma	400	189.88 million	143.29 million	Optionable
BPMC Blueprint Medicines	640	64.58 million	61.22 million	Optionable
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A	337.88 million	N/A	N/A

ARQT, BBIO, BPMC, and TLX Headlines

Recent News About These Companies

Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy

May 7 at 4:13 PM | globenewswire.com

Shareholders that Lost Money on Telix Pharmaceuticals Limited (TLX) Should Contact Levi & Korsinsky About Securities Fraud Investigation - TLX

May 7 at 7:30 AM | accessnewswire.com

ATTENTION Telix Pharmaceuticals Limited Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights

May 6 at 7:30 AM | accessnewswire.com

Telix Pharmaceuticals Limited INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Telix Pharmaceuticals Limited (TLX)

May 5 at 7:25 AM | accessnewswire.com

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Shares Gap Up - Still a Buy?

May 5 at 2:53 AM | marketbeat.com

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Shares Gap Up - Time to Buy?

May 4, 2025 | americanbankingnews.com

Telix Pharmaceuticals Limited INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Telix Pharmaceuticals Limited (TLX)

May 2, 2025 | accessnewswire.com

Telix Pharmaceuticals Limited American Depositary Shares (TLX)

May 1, 2025 | nasdaq.com

TLX STOCK ALERT: Levi & Korsinsky Notifies Telix Pharmaceuticals Limited Investors of an Ongoing Investigation

May 1, 2025 | accessnewswire.com

What is William Blair's Estimate for TLX FY2026 Earnings?

May 1, 2025 | marketbeat.com

William Blair Issues Pessimistic Forecast for TLX Earnings

May 1, 2025 | americanbankingnews.com

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Shares Gap Down - What's Next?

April 30, 2025 | marketbeat.com

TLX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Telix Pharmaceuticals Limited

April 30, 2025 | accessnewswire.com

Telix's Illuccix PSMA-PET Imaging Agent Approved in France

April 28, 2025 | globenewswire.com

Levi & Korsinsky Announces an Investigation on Behalf of Telix Pharmaceuticals Limited (TLX) Shareholders Who May Have Been Affected by Fraud

April 28, 2025 | accessnewswire.com

Telix shares crash 8% on US FDA blow

April 27, 2025 | msn.com

Telix Pharmaceuticals Ltd. ADR

April 23, 2025 | wsj.com

Telix Reports US$186M Q1 Revenue, Up 62% YOY

April 22, 2025 | globenewswire.com

IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate

April 15, 2025 | globenewswire.com

All You Need to Know About Telix Pharmaceuticals Limited (TLX) Rating Upgrade to Buy

April 14, 2025 | zacks.com

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Shares Up 1.4% - Here's Why

April 9, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARQT, BBIO, BPMC, and TLX Company Descriptions

Arcutis Biotherapeutics NASDAQ:ARQT

$13.64 -0.68 (-4.71%)

Closing price 05/7/2025 03:59 PM Eastern

Extended Trading

$13.87 +0.23 (+1.66%)

As of 05:08 AM Eastern

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

BridgeBio Pharma NASDAQ:BBIO

$35.82 -1.12 (-3.02%)

Closing price 05/7/2025 03:59 PM Eastern

Extended Trading

$36.16 +0.34 (+0.95%)

As of 05:00 AM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Blueprint Medicines NASDAQ:BPMC

$99.84 +0.68 (+0.69%)

Closing price 05/7/2025 03:59 PM Eastern

Extended Trading

$99.80 -0.03 (-0.04%)

As of 05:04 AM Eastern

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Telix Pharmaceuticals Limited American Depositary Shares NASDAQ:TLX

$17.75 -0.53 (-2.90%)

Closing price 05/7/2025 04:00 PM Eastern

Extended Trading

$16.86 -0.89 (-4.99%)

As of 04:54 AM Eastern

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time